JP2005528398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528398A5 JP2005528398A5 JP2003584049A JP2003584049A JP2005528398A5 JP 2005528398 A5 JP2005528398 A5 JP 2005528398A5 JP 2003584049 A JP2003584049 A JP 2003584049A JP 2003584049 A JP2003584049 A JP 2003584049A JP 2005528398 A5 JP2005528398 A5 JP 2005528398A5
- Authority
- JP
- Japan
- Prior art keywords
- per
- blood
- antidiabetic
- average
- recorded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- MCHGHPIHLAZAFH-UHFFFAOYSA-N pteroside Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC2=C1OC(CC=1C=CC(O)=CC=1)=C2 MCHGHPIHLAZAFH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2002/000105 WO2003087093A1 (en) | 2002-04-08 | 2002-04-08 | Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005528398A JP2005528398A (ja) | 2005-09-22 |
| JP2005528398A5 true JP2005528398A5 (enExample) | 2009-05-07 |
| JP4309769B2 JP4309769B2 (ja) | 2009-08-05 |
Family
ID=29227416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003584049A Expired - Fee Related JP4309769B2 (ja) | 2002-04-08 | 2002-04-08 | 新規なグルコピラノサイド、その分離方法、それを含む薬物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1495019B1 (enExample) |
| JP (1) | JP4309769B2 (enExample) |
| CN (1) | CN1280290C (enExample) |
| AT (1) | ATE399778T1 (enExample) |
| AU (1) | AU2002246317A1 (enExample) |
| DE (1) | DE60227421D1 (enExample) |
| WO (1) | WO2003087093A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE510834T1 (de) | 2003-03-14 | 2011-06-15 | Astellas Pharma Inc | C-glykosid-derivate zur behandlung von diabetes |
| AU2004261663A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
| EP1679965A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES |
| WO2005012243A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indole-o-glucosides |
| CA2549017A1 (en) | 2003-08-01 | 2005-02-10 | Mona Patel | Substituted indazole-o-glucosides |
| CA2557320C (en) * | 2004-03-04 | 2013-02-05 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivatives for prevention or treatment of hyperglycemia |
| AU2005219779B2 (en) * | 2004-03-04 | 2011-04-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| CA2673498C (en) | 2006-12-21 | 2012-04-24 | Astellas Pharma Inc. | Method for producing c-glycoside derivative and intermediate for synthesis thereof |
| TW201623321A (zh) * | 2014-05-13 | 2016-07-01 | 韓美藥品股份有限公司 | 雙環衍生物及包含其之藥學組成物 |
| CN106674311B (zh) * | 2016-12-27 | 2019-02-05 | 西安交通大学 | 一种苯并呋喃苷类化合物及其制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
-
2002
- 2002-04-08 DE DE60227421T patent/DE60227421D1/de not_active Expired - Lifetime
- 2002-04-08 AU AU2002246317A patent/AU2002246317A1/en not_active Abandoned
- 2002-04-08 EP EP02714415A patent/EP1495019B1/en not_active Expired - Lifetime
- 2002-04-08 AT AT02714415T patent/ATE399778T1/de not_active IP Right Cessation
- 2002-04-08 WO PCT/IN2002/000105 patent/WO2003087093A1/en not_active Ceased
- 2002-04-08 JP JP2003584049A patent/JP4309769B2/ja not_active Expired - Fee Related
- 2002-04-08 CN CNB028291042A patent/CN1280290C/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USD499910S1 (en) | Bed footboard | |
| JP2006526031A5 (enExample) | ||
| NO2017047I1 (no) | Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt | |
| TW200635582A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| EP1498411A4 (en) | DICETOHYDRAZINE DERIVATIVE COMPOUNDS AND MEDICAMENTS CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENTS | |
| EP2298416A3 (en) | Sustained-release tramadol formulations with 24-hour clinical efficacy | |
| CA2472954A1 (en) | Aza-arylpiperazines | |
| JP2007501251A5 (enExample) | ||
| CA2460865A1 (en) | Quinoline derivatives as neuropeptide y antagonists | |
| JP2008513510A5 (enExample) | ||
| JP2005509503A5 (enExample) | ||
| JP2007510699A5 (enExample) | ||
| JP2000159790A5 (enExample) | ||
| JP2004002446A5 (enExample) | ||
| EP2072049A3 (en) | Solid valsartan pharmaceutical compositions | |
| JP2008516004A5 (enExample) | ||
| CA2489140A1 (en) | Dosage form containing pantoprazole as active ingredient | |
| JP2009518415A5 (enExample) | ||
| WO2005039578A3 (en) | Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof | |
| JP2008515980A5 (enExample) | ||
| IL162853A0 (en) | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus | |
| JP2004517961A5 (enExample) | ||
| JP2004026743A5 (enExample) | ||
| JP2005513036A5 (enExample) | ||
| JP2007507472A5 (enExample) |